Compounds Studied in Metabolic and Body-Composition Research

5-Amino-1MQ (also written 5-amino-1-methylquinolinium; class: small-molecule nicotinamide N-methyltransferase inhibitor) is a synthetic quaternary quinolinium salt. Adipotide (also written FTPP; class: peptidomimetic vascular-targeted pro-apoptotic peptide) is a chimeric peptide directed at prohibitin-expressing vasculature. AOD9604 (also written Fragment 176-191; class: synthetic peptide fragment of human growth hormone) corresponds to the C-terminal region of the growth hormone molecule. ARA-290 (also written cibinetide; class: synthetic 11-amino-acid peptide) is an erythropoietin-derived peptide. BPC-157 (also written Body Protection Compound 157; class: synthetic pentadecapeptide) is a stable gastric pentadecapeptide. Cagrilintide (also written AM833; class: long-acting amylin analogue) is a synthetic peptide. CJC-1295 with DAC (also written CJC-1295 Drug Affinity Complex; class: growth hormone-releasing hormone analogue) is a tetrasubstituted peptide. DSIP (also written delta sleep-inducing peptide; class: endogenous nonapeptide) is a short regulatory peptide. Epithalon (also written Epitalon, AEDG; class: synthetic tetrapeptide) is a short alanine-glutamate-aspartate-glycine peptide. Cerebrolysin (class: porcine brain-derived peptide preparation) is a low-molecular-weight neuropeptide fraction. Bacteriostatic water (class: sterile diluent) is water containing 0.9% benzyl alcohol as a bacteriostatic preservative.

The research surveyed here centres on metabolic regulation, body-composition change, and the mitochondrial and inflammatory pathways that accompany them, including GLP-1/GIP receptor agonism, amylin receptor signalling, nicotinamide adenine dinucleotide (NAD+) precursor availability, and mitophagy.

Research Studies

Semaglutide and postpartum cardiometabolic risk after gestational diabetes

A randomized clinical trial (NCT07797036) evaluated immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus in 226 postpartum individuals, randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase, with the primary effectiveness outcome being development of metabolic syndrome at 6 months postpartum [2].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

A multicentre, double-blind, placebo-controlled randomized trial (NCT07770282) evaluated adjunctive oral semaglutide 3 mg once daily added to treatment as usual in patients with schizophrenia on second-generation antipsychotics, assessing 10-year cardiovascular risk (QRISK3), insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks [9].

Tirzepatide and preoperative optimization before one anastomosis gastric bypass

A study (NCT07622992) compared three preoperative strategies before one anastomosis gastric bypass for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care, with the main goal of determining which approach led to the best weight loss one year after surgery, and secondary evaluation of safety, surgical outcomes, and improvement of obesity-related conditions such as diabetes, high blood pressure, and sleep apnea [5].

GLP-1/GIP receptor agonists and obesity-related HFpEF

GLIDE-HF (NCT07787936) is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care in Poland, enrolling patients with obesity-related heart failure with preserved ejection fraction defined by chronic heart failure symptoms or exertional dyspnea, body mass index at least 30 kg/m2, left ventricular ejection fraction at least 50%, and objective evidence of HFpEF using contemporary diagnostic scores (H2FPEF and HFA-PEFF) [8].

Nicotinamide and retinal protection in primary open-angle glaucoma

The NADIR trial (NCT07808333) evaluated whether high-dose nicotinamide added to standard glaucoma therapy slowed the rate of thinning of the inner retinal nerve cell layer compared with standard therapy alone over 12 months in adults with primary open-angle glaucoma already receiving standard eye drops or laser treatment, with participants randomized to nicotinamide tablets by mouth starting at 1.5 grams per day or to standard therapy [3].

Nicotinamide riboside and walking distance in peripheral artery disease

The NICE-PAD II trial (NCT07782671) randomized 250 participants with peripheral artery disease age 50 and older to nicotinamide riboside or placebo for six months, with the primary outcome being change in six-minute walk distance at six-month follow-up and secondary outcomes including Walking Impairment Questionnaire distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [11].

Calcium-HMB plus vitamin D3 and muscle preservation during semaglutide initiation

A randomized, double-blind, placebo-controlled trial (NCT07760948) evaluated whether daily calcium beta-hydroxy-beta-methylbutyrate plus vitamin D3 preserved muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes newly starting semaglutide as part of usual clinical care, with the primary outcome being change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6 and secondary assessments including body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [10].

Fasting modality and mitophagy with mitochondrial DNA dynamics

A study (NCT07638696) investigated how different types of fasting affect mitochondrial clearance and renewal, comparing Ramadan dry fasting, which involves total restriction of both food and fluids from dawn to sunset, with standard 16:8 water-permitted time-restricted feeding, examining blood markers related to mitochondrial DNA and metabolic health across a 30-day period [4].

BPC-157 and tendon healing after rotator cuff repair

A randomized, double-blind, placebo-controlled pilot trial (NCT07803250) investigated the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair in twenty patients, who self-administered subcutaneous injections daily for 90 days following surgery, with all other aspects of care following the standard postoperative pathway [7].

GHK and GHK-Cu blood levels after patch application

A two-part study (NCT07706361) investigated GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults and the efficacy of the X39 patch on GHK and GHK-Cu blood levels compared with placebo, asking what the change in GHK and GHK-Cu levels was from baseline to Day 8 and what the difference in that change was between the X39 patch and placebo [6].

AI-assisted subtyping-directed precision treatment in acute aortic dissection

A prospective multicenter randomized controlled trial (NCT07382375) integrated multi-dimensional data to construct an AI immunoinflammatory subtyping system for acute aortic dissection, in which 300 patients were randomly divided into two groups, with the experimental group receiving subtyping-based precision therapy and the control group using empirical strategies [1].

SYH2069 injection in type 2 diabetes inadequately controlled on metformin

A multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study (NCT07796477) evaluated the efficacy, safety, pharmacokinetics and immunogenicity of SYH2069 Injection in participants with type 2 diabetes mellitus inadequate glycemic control with diet and exercise alone or metformin monotherapy, enrolling 240 subjects stratified by baseline HbA1c levels and prior metformin use [12].

If you are reading this for personal health reasons

The compounds described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
• [2] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [3] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [4] Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding — https://clinicaltrials.gov/study/NCT07638696
• [5] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery — https://clinicaltrials.gov/study/NCT07622992
• [6] Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — https://clinicaltrials.gov/study/NCT07706361
• [7] Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery — https://clinicaltrials.gov/study/NCT07803250
• [8] GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry — https://clinicaltrials.gov/study/NCT07787936
• [9] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [10] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [11] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
• [12] A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin — https://clinicaltrials.gov/study/NCT07796477